Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICS/formoterol versus salbutamol as relief inhaler for mild asthma
ISRCTN29579666Phase 3Completed
- Sponsor
- University of Nottingham
- Start
- Jul 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of budesonide + formoterol, beclometasone dipropionate + formoterol, salbutamol and beclomethasone dipropionate in asthma (2 arms), sponsored by University of Nottingham. Primary endpoint: Time to first severe asthma exacerbation. Started Jul 2023; status: completed.
02
Drugs
budesonide + formoterolbeclometasone dipropionate + formoterolsalbutamolbeclomethasone dipropionate
03
Conditions
asthma
Beyond the preview
Go deeper on ISRCTN29579666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN29579666.